Medovex Obtains CE Mark for DenerveX

Medovex (NASDAQ:MDVX) received a coveted CE Mark approval in Europe for their DenerveX system.
As quoted in the press release:

Patrick Kullmann, Medovex President and COO, stated, “We are clearly pleased to have accomplished this important milestone not just for our shareholders, but for all of those suffering from often debilitating lower back pain associated with Facet Joint Syndrome. The CE Mark indicates a product’s compliance with applicable EU regulations and enables the commercialization of the DenerveX System in European Countries.”
Kullmann continued, “We look forward to initiating sales in the future through our already established international distribution network being able to offer surgeons, pain management specialists and patients an alternative, more cost effective and less invasive treatment option to the current surgical forms of treatment. The CE Mark is clearly the most significant milestone achieved in the company’s history to date.”

Click here to read the full press release.

Source: www.marketwired.com